1. Editor’s Commentary: A Time for Refection and Anticipation

   • J. Rick Turner

   Commentary 01 November 2011 Pages: 687 - 689

2. Commentary: The Real-world Convergence of Comparative Effectiveness Research and Risk-Beneft Assessment

   • John J. Doyle

   Commentary 01 November 2011 Pages: 691 - 696

3. Associate Editor’s Commentary: The Danger of Shorting Drug Shortages

   • Peter J. Pitts

   Commentary 01 November 2011 Pages: 697 - 698

4. Fewer Drugs, Shorter Lives, Less Prosperity: The Impact of Comparative Effectiveness Research on Health and Wealth

   • John Vernon
   • Robert Goldberg
   • Joseph H. Golec

   Commentary 01 November 2011 Pages: 699 - 703

5. Preparing for a Safety Inspection

   • Steve Jolley

   Commentary 01 November 2011 Pages: 705 - 711

6. Letter to the Editor

   • Joanne Zhang
   • Norman Stockbridge

   Letter to the Editor 01 November 2011 Pages: 713 - 715

7. Ten-year Experience of the Evaluation of Ethnic Sensitivity Data

   • Chia-Ling Hsiao
   • Yeong-Liang Lin
   • Kuang-Yang Hsu

   Clinical Trials 01 November 2011 Pages: 717 - 724

8. Optimal Allocation of Prognostic Factors in Randomized Preclinical Animal Studies

   • Zheng Su

   Clinical Trials 01 November 2011 Pages: 725 - 729

9. Platelet Aggregation Quality Control in a Multicenter, Phase 2 Clinical Trial

   • James McRedmond

   Clinical Trials 01 November 2011 Pages: 731 - 740

10. A Longitudinal Model and Graphic for Beneft-risk Analysis, With Case Study

    • Jonathan D. Norton

    Statistics 01 November 2011 Pages: 741 - 747

11. A benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making

    • Andreas Sashegyi

    Statistics 01 November 2011 Pages: 749 - 757

12. Validation of Decision-enabling Tools: Showing That the Model Is Useful

    • Niclas Sjögren
    • Stig Johan Wiklund

    Statistics 01 November 2011 Pages: 759 - 765

13. Evaluation of Drug Adverse Event Intake and Reporting in a Medical Information Service

    • Pamela D. Allen
    • Robert J. Fuentes
    • Greg Susla

    Drug Information 01 November 2011 Pages: 767 - 773

14. Failure to Communicate: Medication Guide or Memory?

    • Louis A. Morris
    • Morris S. Whitcup
    • Keith LaMattina

    Drug Information 01 November 2011 Pages: 775 - 786

15. Content Analysis of Off-label Drug Use: Reporting Print Media Coverage

    • Dipen A. Patel
    • Avani D. Joshi
    • Kunal Saxena

    Drug Information 01 November 2011 Pages: 787 - 796

16. Assessment of Electronic Drug Information Resource Availability in Alabama Pharmacies

    • Peter J. Hughes
    • Michael Kendrach
    • Maisha Kelly Freeman

    Drug Information 01 November 2011 Pages: 797 - 803

17. Clinically Important Effects in New Drug Development

    • Kanae Togo
    • Nobushige Matsuoka
    • Takashi Moriya

    Drug Information 01 November 2011 Pages: 805 - 810

18. Medical Information Services in the Age of Social Media and New Customer Channels

    • Poonam Bordoloi
    • Andrew Gažo
    • Lesley Fierro

    Drug Information 01 November 2011 Pages: 811 - 818

19. Certification for the Medical Science Liaison: An Idea Whose Time Has Come—or Not

    • Jane Chin
    • Kenneth L. Massey
    • Jimmy Black

    Drug Information 01 November 2011 Pages: 819 - 823

20. Review of: Fundamentals of US Regulatory Affairs, 7th ed.

    • Edward Tabor

    Book Review 01 November 2011 Pages: 825 - 826